Evidence map›Paper›PMID 33643815›Full record

ReviewActa pharmaceutica Sinica. B2021

Artemisinin and artemisinin derivatives as anti-fibrotic therapeutics.

David Dolivo, Pamela Weathers, Tanja Dominko

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 125 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Molecules (Basel, Switzerland) · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

David DolivoDepartment of Surgery, Northwestern University-Feinberg School of Medicine, Chicago, IL 60611, USA.
Pamela WeathersDepartment of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester, MA 01609, USA.
Tanja DominkoDepartment of Biology and Biotechnology, Worcester Polytechnic Institute, Worcester, MA 01609, USA.
Worcester Polytechnic Institute · USNorthwestern University · US

Funding

Study how the liver alters bioavailability of artemisinin when delivered from the dried leaves of the plant Artemisia annua vs as pure drug.R15AT008277 · NCCIH · WORCESTER POLYTECHNIC INSTITUTE · PI WEATHERS, PAMELA J · 2014 to 2018
$953k
NCCIH NIH HHS R15 AT008277
6 · The paper itself

Abstract

Fibrosis is a pathological reparative process that can occur in most organs and is responsible for nearly half of deaths in the developed world. Despite considerable research, few therapies have proven effective and been approved clinically for treatment of fibrosis. Artemisinin compounds are best known as antimalarial therapeutics, but they also demonstrate antiparasitic, antibacterial, anticancer, and anti-fibrotic effects. Here we summarize literature describing anti-fibrotic effects of artemisinin compounds in

Indexed as

ALP, alkaline phosphataseALT, alanine aminotransferaseAMPK, AMP-activated protein kinaseArtemisiaArtemisininArtesunateASP, aspartate aminotransferaseBAD, BCL-2-associated agonist of cell deathBDL, bile duct ligationBSA, bovine serum albuminBUN, blood urea nitrogenCCl4, carbon tetrachlorideCol I, type I collagenCTGF, connective tissue growth factorDHA, dihydroartemisininDLA, dried leaf ArtemisiaECM, extracellular matrixEMT, epithelial-to-mesenchymal transitionFibroblastFibrosisFLS, fibroblast-like synoviocyteHA, hyaluronic acidHSC, hepatic stellate cellHUVEC, human umbilical vein endothelial celli.p., intraperitonealLAP, latency-associated peptideLDH, lactate dehydrogenaseMAPK, mitogen-activated protein kinaseMI, myocardial infarctionMMP, matrix metalloproteinasemTOR, mechanistic target of rapamycinMyofibroblastNAG, N-acetyl-β-d-glucosaminidaseNICD, Notch intracellular domainPCNA, proliferating cell nuclear antigenPHN, passive heymann nephritisROS, reactive oxygen speciesScarsCr, serum creatinineSTZ, streptozotocinTGF-βTGF, β-transforming growth factor-βTIMP, tissue inhibitor of metalloproteinaseUUO, unilateral ureteral obstructionα-SMA, smooth muscle α-actin

Identifiers

PMID33643815
PMCPMC7893118
OpenAlexW3083859449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.